Enchi Liu
About
Enchi Liu is a scholar working on Physiology, Molecular Biology and Psychiatry and Mental health.
According to data from OpenAlex, Enchi Liu has authored 42 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Physiology, 17 papers in Molecular Biology and 16 papers in Psychiatry and Mental health. Recurrent topics in Enchi Liu's work include Alzheimer's disease research and treatments (24 papers), Dementia and Cognitive Impairment Research (16 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (7 papers). Enchi Liu is often cited by papers focused on Alzheimer's disease research and treatments (24 papers), Dementia and Cognitive Impairment Research (16 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (7 papers). Enchi Liu collaborates with scholars based in United States, Belgium and United Kingdom. Enchi Liu's co-authors include Ronald S. Black, Nick C. Fox, Clifford R. Jack, Michael Grundman, Jerome Barakos, Leslie M. Shaw, Keith M. Gregg, Mark E. Schmidt, William J. Jagust and Michael W. Weiner and has published in prestigious journals such as Blood, The Lancet Neurology and Journal of Neurology Neurosurgery & Psychiatry.
In The Last Decade
Enchi Liu
40 papers receiving 2.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Enchi Liu United States | 15 | 1.7k | 982 | 535 | 510 | 399 | 42 | 2.6k | ||
| Sergey Shcherbinin United States | 23 | 1.9k 1.1× | 1.1k 1.2× | 462 0.9× | 617 1.2× | 508 1.3× | 95 | 3.1k | ||
| Adam J. Simon United States | 22 | 2.0k 1.2× | 1.4k 1.4× | 469 0.9× | 823 1.6× | 308 0.8× | 39 | 3.1k | ||
| Michio Kanekiyo United States | 12 | 1.8k 1.1× | 1.1k 1.1× | 538 1.0× | 707 1.4× | 534 1.3× | 28 | 3.3k | ||
| Yukitsuka Kudo Japan | 32 | 2.0k 1.2× | 874 0.9× | 408 0.8× | 715 1.4× | 387 1.0× | 110 | 3.1k | ||
| Ronald S. Black United States | 22 | 2.4k 1.4× | 1.1k 1.1× | 715 1.3× | 609 1.2× | 686 1.7× | 46 | 3.3k | ||
| Anton Forsberg Sweden | 23 | 1.4k 0.9× | 1.1k 1.2× | 459 0.9× | 456 0.9× | 252 0.6× | 48 | 2.6k | ||
| Katharina Bürger Germany | 25 | 1.6k 0.9× | 1.4k 1.5× | 417 0.8× | 549 1.1× | 233 0.6× | 51 | 3.0k | ||
| Richard Harvey United Kingdom | 25 | 1.2k 0.7× | 1.2k 1.2× | 510 1.0× | 611 1.2× | 488 1.2× | 56 | 3.3k | ||
| Caroline E. Hope United States | 7 | 2.0k 1.2× | 504 0.5× | 675 1.3× | 689 1.4× | 460 1.2× | 8 | 2.5k | ||
| Jessica B. Langbaum United States | 31 | 2.0k 1.2× | 2.1k 2.1× | 475 0.9× | 419 0.8× | 291 0.7× | 109 | 3.8k |
Countries citing papers authored by Enchi Liu
Since
Specialization
Citations
This map shows the geographic impact of Enchi Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Enchi Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Enchi Liu more than expected).
Fields of papers citing papers by Enchi Liu
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Enchi Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Enchi Liu. The network helps show where Enchi Liu may publish in the future.
Co-authorship network of co-authors of Enchi Liu
This figure shows the co-authorship network connecting the top 25 collaborators of Enchi Liu. A scholar is included among the top collaborators of Enchi Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Enchi Liu. Enchi Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Zhang, Chong, Jianxiang Shi, Kunlun Chen, et al.. (2025). Single-cell analysis reveals that GFAP+ dedifferentiated Schwann cells promote tumor progress in PNI-positive distal cholangiocarcinoma via lactate/HMGB1 axis. Cell Death and Disease. 16(1). 215–215.
2.
Liu, Enchi, et al.. (2024). FUT4 promotes the progression of Cholangiocarcinoma by modulating epithelial-mesenchymal transition. Cell Cycle. 23(2). 218–231.
3.
Liu, Enchi, Chong Zhang, Ruo Feng, et al.. (2024). Promotion of perineural invasion of cholangiocarcinoma by Schwann cells via nerve growth factor. Journal of Gastrointestinal Oncology. 15(3). 1198–1213.
4.
Posner, Holly, Rosie E. Curiel, Chris J. Edgar, et al.. (2017). Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs.. PubMed. 14(1-2). 22–29.
5.
Hüll, Michael, Carl Sadowsky, Heii Arai, et al.. (2017). Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease. Current Alzheimer Research. 14(7). 696–708.
6.
Gertz, Morie A., Raymond L. Comenzo, Heather Landau, et al.. (2017). Organ Biomarker Responses in Patients With Light Chain Amyloidosis Treated With NEOD001 Are Independent of Previous Hematologic Response. Clinical Lymphoma Myeloma & Leukemia. 17(1). e97–e98.
7.
Delnomdedieu, Marielle, Sridhar Duvvuri, Nazem Atassi, et al.. (2016). First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease. Alzheimer s Research & Therapy. 8(1). 12–12.
8.
Pasquier, Florence, Carl Sadowsky, Yahong Peng, et al.. (2016). Two Phase 2 Multiple Ascending–Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer’s Disease. Journal of Alzheimer s Disease. 51(4). 1131–1143.
9.
Gertz, Morie A., Raymond L. Comenzo, Heather Landau, et al.. (2016). NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction: Results from the Expansion Cohort of a Phase 1/2 Study. Blood. 128(22). 644–644.
10.
Arrighi, H. Michael, Jerome Barakos, Frederik Barkhof, et al.. (2015). Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis. Journal of Neurology Neurosurgery & Psychiatry. 87(1). jnnp–2014.
11.
Liu, Enchi, Johan Luthman, Jesse M. Cedarbaum, et al.. (2015). Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB). Alzheimer s & Dementia. 11(7). 840–849.
12.
Liu, Enchi, Ajibade Ashaye, Karin Travers, et al.. (2014). P1‐147: A PROSPECTIVE, SYSTEMATIC LITERATURE REVIEW AND META‐ANALYSES TO EVALUATE GLOBAL AND REGIONAL BRAIN VOLUMES BY STRUCTURAL MRI AS BIOMARKERS OF ALZHEIMER'S DISEASE (AD) PROGRESSION. Alzheimer s & Dementia. 10(4S_Part_9).
13.
Harrison, John, Dorene M. Rentz, Trent McLaughlin, et al.. (2014). Cognition in MCI and Alzheimer’s Disease: Baseline Data from a Longitudinal Study of the NTB. The Clinical Neuropsychologist. 28(2). 252–268.
14.
Novak, Gerald, H. Robert Brashear, Jianing Di, et al.. (2014). IC‐P‐041: EFFICACY AND SAFETY OF MONTHLY SUBCUTANEOUS BAPINEUZUMAB. Alzheimer s & Dementia. 10(4S_Part_6).
15.
Salloway, Stephen, Reisa A. Sperling, Keith M. Gregg, et al.. (2013). P4–417: Incidence and clinical progression of placebo‐treated amyloid‐negative subjects with mild‐to‐moderate Alzheimer's disease (AD): Results from the phase III PET substudies of bapineuzumab and solanezumab. Alzheimer s & Dementia. 9(4S_Part_22).
16.
Sperling, Reisa A., Stephen Salloway, David J. Brooks, et al.. (2012). Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. The Lancet Neurology. 11(3). 241–249.
17.
Weiner, Michael W., Dallas P. Veitch, Paul Aisen, et al.. (2011). The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer s & Dementia. 8(1S). S1–68.
18.
Rinne, Juha O., David J. Brooks, Martin N. Rossor, et al.. (2010). 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. The Lancet Neurology. 9(4). 363–372.
19.
Blennow, Kaj, Henrik Zetterberg, Jenny Wei, et al.. (2010). O3‐05‐01: Immunotherapy with bapineuzumab lowers CSF tau protein levels in patients with Alzheimer's disease. Alzheimer s & Dementia. 6(4S_Part_4).
20.
Liu, Enchi & Linda L. Restifo. (1998). Identification of a broad complex-regulated enhancer in the developing visual system ofDrosophila. Journal of Neurobiology. 34(3). 253–270.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sergey Shcherbinin Breakdown of academic impact, for papers by Adam J. Simon Breakdown of academic impact, for papers by Michio Kanekiyo Breakdown of academic impact, for papers by Yukitsuka Kudo Breakdown of academic impact, for papers by Ronald S. Black Breakdown of academic impact, for papers by Anton Forsberg Breakdown of academic impact, for papers by Katharina Bürger Breakdown of academic impact, for papers by Richard Harvey Breakdown of academic impact, for papers by Caroline E. Hope Breakdown of academic impact, for papers by Jessica B. Langbaum